GlaxoSmithKline's new boss struggles to sell cure for drugmaker

LONDON (Reuters) - Nearly seven months into the job, GlaxoSmithKline's new chief executive is facing a battle to convince investors she has the right prescription for growth at Britain's biggest drugmaker.